<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[generic Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/generic.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to generic]]></description>
	<s:counts start="0" returned="20" found="83" />
	<language>en-us</language>
	<item>
		<title><![CDATA[AmerisourceBergen Corp. F4Q09 (Qtr End 30/09/09) Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-360302.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator Operator Instructions Your first question comes from Eric Coldwell from Baird. Eric Coldwell - Baird First Dave, I think you are marking a milestone this quarter so congratulations on, I believe, 50 quarters now. Dave Yost Thank you very much for noticing, thank you very much...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 03 Nov 2009 13:33:09 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/amerisourcebergen+corp..html"><![CDATA[AmerisourceBergen Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/specialty+business.html"><![CDATA[Specialty Business]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABC</category>
		<category domain="tickers">ABC</category>
	</item>
	<item>
		<title><![CDATA[Winners and Losers in Senate Bill on Pay-for-Delay Deals]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004850/winners-and-losers-in-senate-bill-on-pay-for-delay-deals/]]></link>
		<description><![CDATA[The Senate Judiciary Committee passed a bill that would bar drug companies from paying to prevent generic rivals to their branded drugs from being launched. So called "pay-for-delay" deals prevent cheap generics from reaching the market for years, the bill's proponents argue. By banning the deals, consumers will benefit from...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 16 Oct 2009 08:27:54 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/bill.html"><![CDATA[Bill]]></category>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+senate.html"><![CDATA[U.S. Senate]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Winn-Dixie Stores, Inc. F4Q09 (Qtr End 06/24/09) Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14040_23-334247.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator Operator Instructions Your first question comes from Analyst for Scott Mushkin - Jefferies & Co. Analyst for Scott Mushkin - Jefferies & Co. Just a question on the Jacksonville relaunch, and I know it's early, but can you give us some color on what you're seeing...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 25 Aug 2009 08:25:51 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/winn-dixie+stores+inc..html"><![CDATA[Winn-Dixie Stores Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/analyst.html"><![CDATA[Analyst]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/jefferies+%2526+co..html"><![CDATA[Jefferies & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/currency+%2526+foreign+exchange.html"><![CDATA[Currency & Foreign Exchange]]></category>
		<category domain="http://resources.bnet.com/topic/product+marketing.html"><![CDATA[Product Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WINN</category>
		<category domain="tickers">WINN</category>
	</item>
	<item>
		<title><![CDATA[Shire Q2: The Party's Over as Teva's Generics Decimate Adderall]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003475/shire-q2-the-partys-over-as-tevas-generics-decimate-adderall/]]></link>
		<description><![CDATA[For months, Shire has been trying to defy gravity by jacking up the price of Adderall XR in order to encourage users to switch to its cheaper, new ADHD drug, Vyvanse. This quarter it came down to earth as sales collapsed in the face of generic competition. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 05 Aug 2009 11:50:21 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[GSK Q2: Generics Wreak Havoc; Cost Reductions From Layoffs Spent on Advertising]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003394/gsk-q2-generics-wreak-havoc-cost-reductions-from-layoffs-get-spent-on-advertising/]]></link>
		<description><![CDATA[GlaxoSmithKline's Q2 2009 results, released a few days ago, were well received but within the company's disclosures and investor presentations were some sobering statistics on the ongoing damage that generics are doing to the company, and the progress of its cost-reduction programs. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 31 Jul 2009 14:13:44 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/layoff.html"><![CDATA[Layoff]]></category>
		<category domain="http://resources.bnet.com/topic/advertisement.html"><![CDATA[Advertisement]]></category>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/cost+reduction.html"><![CDATA[Cost Reduction]]></category>
		<category domain="http://resources.bnet.com/topic/workforce+management.html"><![CDATA[Workforce Management]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Medco Health Solutions Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14058_23-326028.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator (Operator's Instructions) Your first question is from Lisa Gill, JP Morgan. Lisa Gill - JP Morgan  Thanks very much and congratulations, guys, in doing it in less than 30 minutes this morning.  Laughter We appreciate that.  Dave, I guess just a couple questions for...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Wed, 29 Jul 2009 09:07:39 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/health+care.html"><![CDATA[Health Care]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/vertical+industries.html"><![CDATA[Vertical Industries]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare+reform.html"><![CDATA[Healthcare Reform]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/medco+health+solutions+inc..html"><![CDATA[Medco Health Solutions Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MHS</category>
		<category domain="tickers">MHS</category>
	</item>
	<item>
		<title><![CDATA[McKesson Corporation F1Q10 (Qtr End 06/30/09) Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-325817.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator instructions Our first question come from Charles Rhyee, your line is open. Jeff Campbell Charles? Operator I apologize. It looks like Charles just disconnected. Our next question comes from Lisa Gill. Your line is open. Lisa Gill &#8211; JPMorgan Hi, thanks very much and congratulations on...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 28 Jul 2009 20:06:17 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/j.p.+morgan+chase+%2526+co..html"><![CDATA[J.P. Morgan Chase & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/margin.html"><![CDATA[Margin]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/mckesson+corp..html"><![CDATA[McKesson Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JPM</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MCK</category>
		<category domain="tickers">JPM,MCK</category>
	</item>
	<item>
		<title><![CDATA[Shire Q1: The Big Fight Against Teva's Generics Begins]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001923/shire-q1-the-big-fight-against-tevas-generics-begins/]]></link>
		<description><![CDATA[Shire, the maker of ADHD drugs Adderall XR and Vyvanse had an excellent Q1 but now faces a challenge: It's two top products are threatened by a generic that Teva brought to market on April 2. The company is also persisting in the U.S with its Daytrana ADHD patch, which...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 04 May 2009 13:03:31 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/manufacturing.html"><![CDATA[Manufacturing]]></category>
		<category domain="http://resources.bnet.com/topic/patches.html"><![CDATA[Patches]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Cardinal Health, Inc., F3Q09 (Qtr End 03/31/09) Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-293724.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator  Operator Instructions.  Your first question comes from the line of Glen Santangelo - Credit Suisse. Glen Santangelo - Credit Suisse  I just have a quick question with respect to CVS, you didn&#8217;t comment at all on the upcoming re-negotiation; Kerry or George may...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 30 Apr 2009 11:39:25 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/cardinal+health+inc..html"><![CDATA[Cardinal Health Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/credit+suisse+group+ag.html"><![CDATA[Credit Suisse Group AG]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/litigation.html"><![CDATA[Litigation]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CAH</category>
		<category domain="tickers">CAH</category>
	</item>
	<item>
		<title><![CDATA[BMS's Bodnar Caught in His Own Lies on Apotex-Plavix Deal]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001614/bmss-bodnar-caught-in-his-own-lies-on-apotex-plavix-deal/]]></link>
		<description><![CDATA[Former Bristol-Myers Squibb svp/strategy Andrew Bodnar faces a year in prison after he pled guilty to lying to the FTC about BMS's generic deal with Apotex.    The conviction carries a lesson for senior drug company executives hoping to put one over on the government: If you're going...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 07 Apr 2009 12:11:38 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[Agreement]]></category>
		<category domain="http://resources.bnet.com/topic/ftc.html"><![CDATA[FTC]]></category>
		<category domain="http://resources.bnet.com/topic/bms.html"><![CDATA[BMS]]></category>
		<category domain="http://resources.bnet.com/topic/apotex.html"><![CDATA[Apotex]]></category>
		<category domain="http://resources.bnet.com/topic/plavix.html"><![CDATA[Plavix]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[The Pfizer-Shire Deal Worst-Case Scenario]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000569/the-pfizer-shire-deal-worst-case-scenario/]]></link>
		<description><![CDATA[Earlier this week shares of Shire rose on rumors that Pfizer may be interested in acquiring the company, which is best-known for its ADHD drug Adderall XR. The notion that Pfizer is in acquisition mode has been driving people crazy for days. (See BNET's coverage of Pfizer Pfever here.) ...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 07 Jan 2009 14:00:06 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/medicaid.html"><![CDATA[Medicaid]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/adhd.html"><![CDATA[ADHD]]></category>
		<category domain="http://resources.bnet.com/topic/vyvanse.html"><![CDATA[Vyvanse]]></category>
		<category domain="http://resources.bnet.com/topic/barr.html"><![CDATA[Barr]]></category>
		<category domain="http://resources.bnet.com/topic/cola.html"><![CDATA[Cola]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Merck Eyes Generics, Pfizer Delays Layoffs, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000481/pharma-roundup-merck-eyes-generics-pfizer-delays-layoffs-and-more/]]></link>
		<description><![CDATA[Merck launches generics business, Pfizer delays layoffs, Europe can continue to repackage drugs. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 09 Dec 2008 16:54:04 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/layoff.html"><![CDATA[Layoff]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/repackaging.html"><![CDATA[Repackaging]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/workforce+management.html"><![CDATA[Workforce Management]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">MRK,PFE</category>
	</item>
	<item>
		<title><![CDATA[POZEN Inc. Q3 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-248566.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator  Operator instructions Your first question comes from the line of Angela Larson of SFG. Your line is open. Angela Larson &#8211; SFG  Good morning and thanks for taking questions. John Plachetka  Good morning Angela Larson &#8211; SFG  Good morning. I was hoping...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Wed, 12 Nov 2008 00:52:13 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/question.html"><![CDATA[Question]]></category>
		<category domain="http://resources.bnet.com/topic/pozen+inc..html"><![CDATA[Pozen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/treximet.html"><![CDATA[Treximet]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/question.html"><![CDATA[Question]]></category>
		<category domain="http://resources.bnet.com/topic/pozen+inc..html"><![CDATA[Pozen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/treximet.html"><![CDATA[Treximet]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">POZN</category>
		<category domain="tickers">POZN</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Daiichi and Ranbaxy, Generics and Staff Shake-Ups at Novartis, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000311/pharma-roundup-daiichi-and-ranbaxy-generics-and-staff-shake-ups-at-novartis-and-more/]]></link>
		<description><![CDATA[Daiichi buys 20% stake in Ranbaxy; at Novartis, executives and jobs on the move, and sinking profits from generics; Wisconsin doctors ban gifts from pharma companies. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 20 Oct 2008 16:52:30 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/daiichi.html"><![CDATA[Daiichi]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/daiichi.html"><![CDATA[Daiichi]]></category>
		<category domain="http://resources.bnet.com/topic/vertical+industries.html"><![CDATA[Vertical Industries]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/enterprise+software.html"><![CDATA[Enterprise Software]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[Software]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Generics at Pfizer, Risk-taking at Lilly, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000301/pharma-roundup-generics-at-pfizer-risk-taking-at-lilly-and-more/]]></link>
		<description><![CDATA[Pfizer boosting production of generics; CEO says Lilly takes bets "every day"; three new major blood clot treatments in late-stage trials; BMS decreasing international ops? by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 16 Oct 2008 15:51:58 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/mergers+%2526+acquisitions.html"><![CDATA[Mergers & Acquisitions]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/marketing+research.html"><![CDATA[Marketing Research]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/financial+services.html"><![CDATA[Financial Services]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[GlaxoSmithKline Bets Solzira Can Win Where Requip Failed]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000224/glaxosmithkline-bets-solzira-can-win-where-requip-failed/]]></link>
		<description><![CDATA[GlaxoSmithKline's announcement yesterday that it is submitting a new drug application for Solzira to the FDA for the treatment of Restless Legs Syndrome raises a question: What was wrong with its old treatment for RLS, Requip, launched only in 2005?    The short answer is that it was...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 17 Sep 2008 11:52:17 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advertisement.html"><![CDATA[Advertisement]]></category>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/requip.html"><![CDATA[Requip]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/nielsen+monitor-plus.html"><![CDATA[Nielsen Monitor-Plus]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="tickers">GSK</category>
	</item>
	<item>
		<title><![CDATA[Shire's Big Gamble on ADHD Drug Vyvanse]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000202/shires-big-gamble-on-adhd-drug-vyvanse/]]></link>
		<description><![CDATA[One of the recent unheralded successes of the drug world was Shire Pharmaceuticals' launch of Vyvanse, a new, long-acting treatment for attention deficit and hyperactivity disorder. The fact that so little attention has been paid to Vyvanse is a shame because the take-up of this drug has been impressive --...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 04 Sep 2008 09:03:49 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/drug.html"><![CDATA[Drug]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/vyvanse.html"><![CDATA[Vyvanse]]></category>
		<category domain="http://resources.bnet.com/topic/sanofi.html"><![CDATA[Sanofi]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Innovation Would Be the Best Method to Fight Generics' Primacy in the Latin American Cardiovascular Drugs Markets]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_April_16/ai_n25156122]]></link>
		<description><![CDATA[BUENOS AIRES, Argentina -- Latin American countries, due to their desire to mimic the lifestyles of developed countries, are increasingly falling prey to cardiovascular diseases CVDs. This situation is providing valuable opportunities to pharmaceutical companies to develop drugs that can reduce drug interactions and offer better efficacy and safety profile....]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 16 Apr 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/e-mail.html"><![CDATA[E-mail]]></category>
		<category domain="http://resources.bnet.com/topic/frost+%2526+sullivan.html"><![CDATA[Frost & Sullivan]]></category>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[generic]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/innovation.html"><![CDATA[innovation]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
	</item>
	<item>
		<title><![CDATA[Job Search With Least Effort]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=914967]]></link>
		<description><![CDATA[As a job seeker, the natural tendency is to prepare a resume as fast as possible and shoot it out to as many employers as possible. When you do that you create two problems. First, a resume prepared in a hurry is likely to be long, complicated, unfocused, and superficial...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Tue, 01 Jan 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/job.html"><![CDATA[Job]]></category>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/job+search.html"><![CDATA[Job Search]]></category>
		<category domain="http://resources.bnet.com/topic/recruitment+%2526+selection.html"><![CDATA[Recruitment & Selection]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/workforce+management.html"><![CDATA[Workforce Management]]></category>
	</item>
	<item>
		<title><![CDATA[IMPAX Submits Additional Information to FDA Related to ANDA For Generic Version of OpanaŽ ER]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Dec_6/ai_n27467276]]></link>
		<description><![CDATA[HAYWARD, Calif. -- IMPAX Laboratories, Inc. (OTC:IPXL) today announced that it has submitted information to the U.S. Food and Drug Administration FDA in response to the notice of rescission related to IMPAX's Abbreviated New Drug Application ANDA for oxymorphone hydrochloride extended-release tablets CII, a generic version of Opana[R] ER. As...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 06 Dec 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
</channel>
</rss>
